首页> 外文期刊>Blood purification >Debate forum: carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy.
【24h】

Debate forum: carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy.

机译:辩论论坛:肉毒碱补充剂尚未在长期透析治疗的患者中证明有效。

获取原文
获取原文并翻译 | 示例
           

摘要

The database for carnitine supplements in dialysis includes no large-scale randomized trials and no registered trials. Medical practitioners prefer to make treatment decisions based on the outcome of randomized clinical trials, with appropriate controls. Furthermore, registered trials provide a further level of integrity, since trial registration avoids publication bias by ensuring that all outcomes are reported, including trials that are not completed. Positive effects reported from carnitine administration in dialysis patients include decreased erythropoietin dose, increased hematocrit, less intradialytic hypotension, and less fatigue. The evidence for carnitine effectiveness is limited to trials that are mostly open-label and that include no more than a total of 1,000 patients. An analysis of recent carnitine administrations to patients in a large dialysis practice database indicates no overall change in hemoglobin or erythropoietin dose following 6 months of carnitine administration. As outcomes ofcontrolled trials with appropriate power to examine for the benefits of carnitine are not yet available, the dialysis practitioner cannot justify the administration of carnitine.
机译:透析中肉碱补充剂的数据库没有大规模的随机试验,也没有注册的试验。执业医师更愿意根据随机临床试验的结果,在适当的控制下做出治疗决定。此外,已注册的试验还提供了更高的完整性,因为试验注册通过确保报告所有结果(包括尚未完成的试验)来避免发表偏见。肉毒碱治疗对透析患者的积极影响包括减少促红细胞生成素剂量,增加血细胞比容,减少透析内低血压和减少疲劳。肉碱有效性的证据仅限于大部分为开放标签的试验,且总共不超过1,000名患者。大型透析实践数据库中最近对患者的肉碱施用量分析表明,服用肉碱6个月后,血红蛋白或促红细胞生成素剂量没有总体变化。由于尚无具有适当能力检查肉碱益处的对照试验结果,透析医生无法证明服用肉碱的合理性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号